

# New Venturetec

## NET ASSET VALUE - April 15, 2019

Shares issued private	4,500,000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500,000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
Shares issued conversion	<u>1,263,157</u>	Price: CHF 9.50 (ex.rate 1.00)	<u>USD 11'999'992</u>
	<b>6,263,157</b>		<b>USD 130'499'992</b>

<b>Total paid in capital</b>	<b>USD</b>	<b>130,499,992</b>
------------------------------	------------	--------------------

Realized gain* (since inception to date)	USD	75,269,925.93
Realized loss* (since inception to date)	USD	109,585,211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	54,718,985.36
Unrealized loss	USD	<u>0.00</u>
<b>Total appreciation</b>	<b>USD</b>	<b>54,718,985.36</b>

### NAV

Cost of investments	USD	28,475,733.64
Appreciation of investments	USD	<u>54,718,985.36</u>
Estimated value of investments	USD	<b>83,194,719.00</b>
Convertible Notes	USD	-1,276,720.61
Loan	USD	-7,706,291.70
Bank Loan	USD	0.00
Accrued expenses	USD	-134,869.00
Accounts receivables	USD	0.00
Cash at bank	USD	<u>73,893.87</u>
<b>Estimated value</b>	<b>USD</b>	<b>74,150,731.57</b>
<b>NAV per share USD</b>		<b>11.84</b>
<b>NAV per share CHF</b>		<b>11.85</b>

Exchange rate USD/CHF	1.0011
<b>Closing Market Price April 15, 2019</b>	<b>CHF 8.70</b>

## New Venturetec NAV - April 15, 2019

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23,780,932.93	83.5	4,103,301 Common Shares	5.80	19.00	54,181,786.07	77,962,719.00	93.6
2. Myriad Genetics	4,694,800.71	16.5	160,000 Shares	29.34	32.70	537,199.29	5,232,000.00	6.3
<b>TOTAL</b>	<b>28,475,733.64</b>	<b>100.0</b>				<b>54,718,985.36</b>	<b>83,194,719.00</b>	<b>99.9</b>